Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports

Ali Al‐janabi; Alexander M. Marsland

doi:10.1002/ccr3.2871

Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports

Ali Al‐janabi, Alexander M. Marsland

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Cutaneous adverse events to dupilumab can be varied; this necessitates keeping a broad differential diagnosis to identify seemingly paradoxical reactions. It may be possible to treat the adverse event concurrently without stopping dupilumab.

Original language	English
Pages (from-to)	1458-1460
Journal	Clinical case reports
Volume	8
Issue number	8
DOIs	https://doi.org/10.1002/ccr3.2871 https://doi.org/10.1002/ccr3.v8.8
Publication status	Published - 9 May 2020

Access to Document

10.1002/ccr3.2871Licence: CC BY
10.1002/ccr3.v8.8

https://onlinelibrary.wiley.com/doi/10.1002/ccr3.2871

Cite this

@article{feac31c57859431885357067ebfc49cb,

title = "Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports",

abstract = "Cutaneous adverse events to dupilumab can be varied; this necessitates keeping a broad differential diagnosis to identify seemingly paradoxical reactions. It may be possible to treat the adverse event concurrently without stopping dupilumab.",

author = "Ali Al‐janabi and Marsland, {Alexander M.}",

year = "2020",

month = may,

day = "9",

doi = "10.1002/ccr3.2871",

language = "English",

volume = "8",

pages = "1458--1460",

journal = "Clinical case reports",

issn = "2050-0904",

publisher = "John Wiley & Sons Ltd",

number = "8",

}

TY - JOUR

T1 - Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports

AU - Al‐janabi, Ali

AU - Marsland, Alexander M.

PY - 2020/5/9

Y1 - 2020/5/9

N2 - Cutaneous adverse events to dupilumab can be varied; this necessitates keeping a broad differential diagnosis to identify seemingly paradoxical reactions. It may be possible to treat the adverse event concurrently without stopping dupilumab.

AB - Cutaneous adverse events to dupilumab can be varied; this necessitates keeping a broad differential diagnosis to identify seemingly paradoxical reactions. It may be possible to treat the adverse event concurrently without stopping dupilumab.

U2 - 10.1002/ccr3.2871

DO - 10.1002/ccr3.2871

M3 - Article

SN - 2050-0904

VL - 8

SP - 1458

EP - 1460

JO - Clinical case reports

JF - Clinical case reports

IS - 8

ER -

Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports

Abstract

Access to Document

Fingerprint

Cite this